ArticleJournal for immunotherapy of cancer2016
Cancer immunotherapy trials: leading a paradigm shift in drug development.
Article in Journal for immunotherapy of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds.Frontiers in oncology · 2022Pooled it
- Immunotherapy Decision-Making Experiences of Patients With Cancer and Their Family Caregivers: A Qualitative Study.The journal of nursing research : JNR · 2025Article
- Computationally integrating radiology and pathology image features for predicting treatment benefit and outcome in lung cancer.NPJ precision oncology · 2025Article
- Targeting Cbl-b in cancer immunotherapy.Journal for immunotherapy of cancer · 2023Review
- Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Advancing microfluidic diagnostic chips into clinical use: a review of current challenges and opportunities.Lab on a chip · 2022Review
- Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity.Journal for immunotherapy of cancer · 2022Article
- Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?British journal of clinical pharmacology · 2020Review
- Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies.Contemporary clinical trials communications · 2020Review
- Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies.Pharmaceutical medicine · 2020Article
- Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin.Diseases (Basel, Switzerland) · 2019Article
- Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics?Journal of leukocyte biology · 2019Review
- Phase II trial design with growth modulation index as the primary endpoint.Pharmaceutical statistics · 2019Article
- Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.Frontiers in immunology · 2019Review
- Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.Current oncology (Toronto, Ont.) · 2018Review
- Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).International journal of oncology · 2018Review
- The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy.Emerging topics in life sciences · 2017Article
- Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.Clinical orthopaedics and related research · 2017Article
- Patent trend and competitive analysis of cancer immunotherapy in the United States.Human vaccines & immunotherapeutics · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.